Literature DB >> 29936581

Haloperidol and delirium in the ICU: the finger pointing to the moon.

Nicola Latronico1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29936581     DOI： 10.1007/s00134-018-5276-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  14 in total

1.  Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.

Authors:  X Xiberas; J L Martinot; L Mallet; E Artiges; C Loc'H; B Mazière; M L Paillère-Martinot
Journal:  Br J Psychiatry       Date:  2001-12       Impact factor: 9.319

2.  Does this critically ill patient with delirium require any drug treatment?

Authors:  Jorge I F Salluh; Nicola Latronico
Journal:  Intensive Care Med       Date:  2018-07-24       Impact factor: 17.440

3.  History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia.

Authors:  Bertha K Madras
Journal:  J Hist Neurosci       Date:  2013       Impact factor: 0.529

4.  Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits.

Authors:  Heike Tost; Dieter F Braus; Shabnam Hakimi; Matthias Ruf; Christian Vollmert; Fabian Hohn; Andreas Meyer-Lindenberg
Journal:  Nat Neurosci       Date:  2010-06-06       Impact factor: 24.884

Review 5.  Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure.

Authors:  José R Maldonado
Journal:  Int J Geriatr Psychiatry       Date:  2017-12-26       Impact factor: 3.485

6.  Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disability.

Authors:  Christopher G Hughes; Mayur B Patel; Nathan E Brummel; Jennifer L Thompson; J Brennan McNeil; Pratik P Pandharipande; James C Jackson; Rameela Chandrasekhar; Lorraine B Ware; E Wesley Ely; Timothy D Girard
Journal:  Intensive Care Med       Date:  2018-03-09       Impact factor: 17.440

7.  Systemic infection and delirium: when cytokines and acetylcholine collide.

Authors:  Willem A van Gool; Diederik van de Beek; Piet Eikelenboom
Journal:  Lancet       Date:  2010-02-27       Impact factor: 79.321

8.  The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.

Authors:  Francisco López-Muñoz; Cecilio Alamo
Journal:  Brain Res Bull       Date:  2009-01-30       Impact factor: 4.077

9.  Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.

Authors:  Marie O Collet; Jesús Caballero; Romain Sonneville; Fernando A Bozza; Peter Nydahl; Anna Schandl; Hilden Wøien; Giuseppe Citerio; Mark van den Boogaard; Johanna Hästbacka; Matthias Haenggi; Kirsten Colpaert; Louise Rose; Marija Barbateskovic; Theis Lange; Aksel Jensen; Martin B Krog; Ingrid Egerod; Helle L Nibro; Jørn Wetterslev; Anders Perner
Journal:  Intensive Care Med       Date:  2018-05-16       Impact factor: 17.440

Review 10.  Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment.

Authors:  José R Maldonado
Journal:  Crit Care Clin       Date:  2008-10       Impact factor: 3.598
View more
  2 in total

1.  Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats.

Authors:  Atsushi Nishigaki; Takashi Kawano; Hideki Iwata; Bun Aoyama; Daiki Yamanaka; Hiroki Tateiwa; Marie Shigematsu-Locatelli; Satoru Eguchi; Fabricio M Locatelli; Masataka Yokoyama
Journal:  J Anesth       Date:  2019-05-02       Impact factor: 2.078

2.  Butorphanol versus Propofol in Patients Undergoing Noninvasive Ventilation: A Prospective Observational Study.

Authors:  Xiaohong Wang; Jianbiao Meng
Journal:  Int J Gen Med       Date:  2021-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.